Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06630104
Recruiting
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Not applicable · United States · 7 sites
Registry update: 1 Oct 2026
NCT07270263
Recruiting
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Not applicable · Poland · 1 site
Registry update: 26 Dec 2025
NCT06251076
Recruiting
Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4 · Canada · 1 site
Registry update: 10 Dec 2025
NCT05909059
Recruiting
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 · United States · 1 site
Registry update: 14 Oct 2026
NCT06911710
Recruiting
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1/2 · China · 1 site
Registry update: 4 Apr 2025
2024-515219-23-00
Recruiting
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.
Phase 1 · France · 5 sites
Registry update: 15 Jul 2026
NCT06350994
Recruiting
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Not applicable · France · 1 site
Registry update: 2 Sept 2025
NCT06679829
Recruiting
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Phase 2 · United States · 7 sites
Registry update: 1 Oct 2026
NCT06518551
Recruiting
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Phase 1 · United States · 3 sites
Registry update: 2 Nov 2026
NCT06142396
Recruiting
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Early phase 1 · United States · 1 site
Registry update: 12 Mar 2026
NCT06767254
Recruiting
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Not applicable · Italy · 4 sites
Registry update: 9 Jan 2025
NCT06630806
Recruiting
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Phase 1 · Australia, Canada, Spain, France, Israel, Italy, United States · 19 sites
Registry update: 25 Mar 2026
2024-514702-31-00
Recruiting
Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure
Phase 2 · Austria · 1 site
Registry update: 29 Oct 2024
NCT06644118
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1 · China · 3 sites
Registry update: 8 Nov 2024
NCT07139509
Recruiting
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 25 Nov 2025
NCT06574126
Recruiting
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Phase 2 · Spain · 1 site
Registry update: 26 Oct 2024
NCT06262789
Recruiting
RAT-HEMATO : Return to Work After Malignant Hemopathy
Not applicable · France · 10 sites
Registry update: 4 Sept 2026
NCT06581640
Recruiting
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 25 Sept 2024
2022-501811-14-00
Recruiting
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Phase 1/2 · Belgium, Netherlands · 4 sites
Registry update: 2 Sept 2026
NCT06597916
Recruiting
RSV Vaccination in Immunocompromised Patients.
Phase 2 · Austria · 1 site
Registry update: 27 Nov 2024

Ordered by registry start date. Freshness and sponsorship never change the order.